Selective Visualization of ROR1-Positive TNBC of the Mesenchymal-Like Subtype Using Peptide-Based 68 Ga-PET Radiotracers
- 29 June 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (13) , 15961-15973
Abstract
Triple-negative breast cancer (TNBC) lacks effective molecular targets for imaging. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is overexpressed in the mesenchymal-like (claudin-low) subtype of TNBC. Here, we developed two optimized linear peptide radiotracers, DR1 and DR2, derived from the complementarity-determining regions (CDR) of an anti-ROR1 antibody, conjugated with DOTA and labeled with 68Ga. Both peptides showed nanomolar binding affinities (KD = 93.4 ± 8.2 nM for DR1 and 38.0 ± 4.6 nM for DR2) and favorable target-binding properties. [68Ga]Ga-DOTA-DR2 exhibited excellent in vitro stability (≥95% radiochemical purity after 4 h in human serum), rapid in vivo clearance (t1/2β = 0.66 ± 0.11 h), and specific cellular uptake. Micro-PET/CT imaging in MDA-MB-231 xenograft mice revealed rapid tumor visualization, with a peak tumor uptake of 2.75 ± 0.61 %ID/g at 1 h and a tumor-to-muscle ratio of 7.98 at 2 h. Blocking studies confirmed ROR1-specific targeting. Collectively, [68Ga]Ga-DOTA-DR2 may represent a promising PET tracer for imaging ROR1-positive mesenchymal-like TNBC, providing a foundation for further optimization.Keywords
Funding Information
- Natural Science Foundation of Chongqing Municipality (CSTB2024NSCQKJFZZDX0046)
- Natural Science Foundation of Jiangsu Province (BK20251585)
- National Natural Science Foundation of China (12405405)
- National Natural Science Foundation of China (82204195)
- National Natural Science Foundation of China (82272038)
- National Natural Science Foundation of China (82504586)
- Nanjing Health Technology Development Special Fund Project (YKK23117)
- Mianyang Central Hospital Open Project (2023HYX013)
This publication has 38 references indexed in Scilit:
- Radioligand as a Unique Rising Modality for Cancer Diagnosis and Treatment2025
- Peptide therapeutics: current status and future opportunity with focus on nose-to-brain delivery☆Peptides, 2025
- Advancements in clinical research and emerging therapies for triple-negative breast cancer treatmentEuropean Journal of Pharmacology, 2024
- Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapiesScience China Life Sciences, 2024
- Screening for Breast CancerJAMA, 2024
- Advances in Radioligand Theranostics in OncologyMolecular Diagnosis & Therapy, 2024
- Radiolabeled peptide probe for tumor imagingChinese Chemical Letters, 2022
- Expression of ROR1 has prognostic significance in triple negative breast cancerVirchows Archiv, 2016
- ROR1, an embryonic protein with an emerging role in cancer biologyProtein & Cell, 2014
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009